XBIO
Xenetic Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+0.86%Aug 7, 2026, 12:35 UTC
Xenetic Biosciences reported financial results for the quarter ended June 30, 2026, and provided a corporate update on its DNase platform development strategy.
Source:Jun 4, 2026, 12:40 UTC
PeriNess Ltd., collaboration partner of Xenetic Biosciences, received approval from the Israeli Ministry of Health to conduct an investigator-initiated study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma.